Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.41 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209948 | 0.88 | GPR52 (0.48) | BRAFGPR52SCDMEN1ALDH1A1 | |
| SCHEMBL3219231 | 0.86 | GPR52 (0.69) | BRAFGPR52MRGPRX4SCD | |
| SCHEMBL1849738 | 0.85 | GPR52 (0.55) | GPR52NR4A2MRGPRX4KMOLIPG | |
| SCHEMBL1849472 | 0.80 | CAMKK2 (0.44) | BRAFKMO | |
| SCHEMBL1850856 | 0.79 | GPR52 (0.51) | GPR52NR4A2MRGPRX4KDM4CSCD | |
| SCHEMBL1853402 | 0.79 | GPR52 (0.75) | GPR52NR4A2ADORA2A | |
| SCHEMBL3198362 | 0.77 | GPR52 (0.61) | GPR52NR4A2MRGPRX4LIPGADORA2A | |
| SCHEMBL1848214 | 0.77 | GPR52 (0.74) | GPR52NR4A2MRGPRX4LIPGADORA2A | |
| SCHEMBL3210335 | 0.77 | GPR52 (0.58) | BRAFGPR52ADORA2ASCD | |
| SCHEMBL1847806 | 0.77 | GPR52 (0.56) | GPR52NR4A2MRGPRX4LIPGADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | BRAF 4083/4885GPR52 1/4885NR4A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.